The 2025-2030 World Outlook for Peripheral Neuropathy Treatments - Image 1

Out of stock

This item is currently unavailable

The 2025-2030 World Outlook for Peripheral Neuropathy Treatments

Subjects

Out of stock

Price data last checked 29 day(s) ago - will refresh soon

View at Amazon

One email. No newsletter. No nudges.

Gone for 220 days. Could come back at any time — we're watching for you.

Out of stock 220 days · last price £790 · longest previous gap was 1 days

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 702 days · 702 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 702 days • 1 price levels

Days at Price

Price Analysis

Most common price: £790 (702 days, 100.0%)

Price range: £790 - £790

Price levels: 1 different prices over 702 days

Description

This study covers the world outlook for peripheral neuropathy treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of peripheral neuropathy treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Assertio Therapeutics, Baxter International, Biogen, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, and Sanofi. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZ2LRLHN
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 29 April 2024

The 2025-2030 World Outlook for Peripheral Neuropathy Treatments

Gone for 220 days. Could come back at any time — we're watching for you.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Bioengineered Monoclonal Antibodies Protein Drugs in Japan

The 2023-2028 Outlook for Drug Delivery Products for US Zip Codes

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs in China

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs for US Zip Codes

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs in India

The 2026-2031 World Outlook for High Potency APIs (HPAPIs)

The 2023-2028 Outlook for Antidepressant and Anti-Anxiety Drugs in Japan

The 2023-2028 World Outlook for Pain-Relieving Lidocaine Patches

The 2023-2028 Outlook for Alzheimer's Treatments in the United States

The 2023 Report on Pharma Contract Sales: World Market Segmentation by City

Dorosz guide pratique des medicaments 2023, 42e ed

The 2023-2028 Outlook for Polycarbonate Vial Adaptors for Reconstitution Drugs in the United States

Pharmaceutical Science to Improve the Human Condition: Prix Galien 2011, Volume 1263 (Annals of the New York Academy of Sciences)

Dorosz Guide pratique des médicaments 2024, 43e éd.

The 2023 Report on E-Pharma: World Market Segmentation by City

The 2023-2028 Outlook for Anti-Arthritic Drugs in Japan

dorosz guide pratique des medicaments 2021, 40e ed

The 2023-2028 Outlook for Premature Ejaculation Treatments for US Zip Codes

The 2023 Report on Transdermal Patches: World Market Segmentation by City

World Scientific Strategic Marketing Specialty Pharmaceuticals Book

Mastering Strategic Marketing For Specialty Pharmaceuticals: A Hands-on Guide

Pharmaceutical Science to Improve the Human Condition: Prix Galien 2010, Volume 1222: 77 (Annals of the New York Academy of Sciences)

Davis's Canadian Drug Guide for Nurses

Dorosz Guide pratique des médicaments 2025, 44e éd.